Status: Current Investments

Clinical-stage biotechnology company developing purpose-built therapeutics by leveraging cutting edge computational biology tools, a focus on human tissue, and expertise in immunobiology.

Clinical-stage biotechnology company developing treatments for Claudin-1 positive (CLDN1+) tumors and organ fibrosis.

Clinical-stage biotechnology company discovering and developing novel therapies to treat immune-mediated chronic inflammatory diseases.

A full-service, digitally-powered pharmacy providing an easier, more supportive and more affordable pharmacy experience.

Clinical-stage company developing transformative medicines that dramatically improve the lives of patients with life-altering immune diseases.

Completed reverse merger in 2023

Commercial-stage life science company focused on manufacturing scalable single-use bioreactors and providing process development services to cell therapy clients.

Global contract development and manufacturing organization for radiotherapeutics.

Health prediction company utilizing proteomics and advanced statistical techniques to better predict and improve health outcomes.

Commercial-stage life science company dedicated to bringing an innovative primary cell control solution to the immunotherapy market to support research, drug discovery, and cell manufacturing.

Disruptive animal health provider delivering innovative diagnostic solutions to veterinarians and pet owners across the United States.